Continued dual antiplatelet therapy beyond 1 year postcoronary stenting benefits patients with diabetes
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Patients with diabetes are likely to benefit from additional use of dual antiplatelet therapy beyond the currently recommended 6-12 months following implantation of drug-eluting stents, although they may benefit less than those without diabetes.
Prespecified analysis on the effects of continued thienopyridine in diabetes patients participating in the Dual Antiplatelet Therapy (DAPT) Study, which compared 30 vs 12 months of thienopyridine therapy in addition to aspirin following coronary stenting for the prevention of stent thrombosis or major adverse cardiovascular and cerebrovascular events (MACCE), a composite of all-cause mortality, MI, or stroke.
After stent placement and 12 months with open-label thienopyridine plus aspirin, 11,648 patients were randomly assigned to continued thienopyridine or placebo plus aspirin for 18 more months.
Effectiveness endpoints included incidence of stent thrombosis and incidence of MACCE and its components. Primary safety endpoin...